Clinical implications and guidelines for CKD in type 2 diabetes
Nephrology Dialysis Transplantation · 28.02.2023 · 38 (3) · 542-550
DOI: 10.1093/ndt/gfac285 ↗Kurz gefasst
Leitlinie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.10.2022. Verfasst von Rong M Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, MO, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: American Heart Association, Novo Nordisk, Dexcom.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is a complication of type 2 diabetes (T2D) with high morbidity and mortality. The prevalence of CKD in T2D is increasing due to rising numbers of persons with T2D. Multiple clinical trials have been conducted testing novel therapies to reduce the progression of CKD, cardiovascular morbidity, in particular hospitalization for heart failure, and mortality. Results of these clinical trials have informed guidelines for the management of CKD in T2D.
Methods
The epidemiology of CKD in T2D and the process of guideline writing, including data gathering, grading and consensus development, were reviewed. Recent guidelines for the management of CKD in T2D that include recent renal outcome clinical trials are reported, along with supporting evidence.
Results
All current guidelines recommend annual screening for CKD, control of blood pressure and glucose, although the target levels and background therapy recommendations vary. Renin–angiotensin system (RAS) inhibition is uniformly recommended. Sodium-glucose cotransporter-2 (SGLT2) inhibition with proven agents is recommended by all guidelines, with minor variations in suggested estimated glomerular filtration rate and albuminuria levels. Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist with renal outcome data, is recommended by the most recent guideline available.
Conclusions
Current guidelines continue to recommend screening for CKD, blood pressure control using RAS inhibition as first-line therapy, and glucose control. SGLT2 inhibition and finerenone are recent additions to current guidelines to improve CKD outcomes in T2D, based on robust clinical trial data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, MO, USA.
- Steno Diabetes Center Copenhagen, Borgmester Ib Juuls Vej 83, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Rong M Zhang, Frederik Persson, Peter Rossing
Förderung
- American Heart Association
- Novo Nordisk
- Dexcom
- Medtronic
- Beta Bionics
- JDRF
- Washington University
- Burroughs Wellcome Fund
Zitieren
APA
Zhang, R. M., Persson, F., McGill, J. B., & Rossing, P. (2023). Clinical implications and guidelines for CKD in type 2 diabetes. Nephrology Dialysis Transplantation, 38(3), 542-550. https://doi.org/10.1093/ndt/gfac285
Vancouver
Zhang RM, Persson F, McGill JB, Rossing P. Clinical implications and guidelines for CKD in type 2 diabetes. Nephrology Dialysis Transplantation. 2023;38(3):542-550. doi:10.1093/ndt/gfac285
BibTeX
@article{Zhang2023,
author = {Zhang, Rong M and Persson, Frederik and McGill, Janet B and Rossing, Peter},
title = {Clinical implications and guidelines for CKD in type 2 diabetes},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {3},
pages = {542--550},
doi = {10.1093/ndt/gfac285}
}
EUVIMED